1. Home
  2. BULLZ vs ZVSA Comparison

BULLZ vs ZVSA Comparison

Compare BULLZ & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BULLZ
  • ZVSA
  • Stock Information
  • Founded
  • BULLZ N/A
  • ZVSA 2014
  • Country
  • BULLZ United States
  • ZVSA United States
  • Employees
  • BULLZ N/A
  • ZVSA N/A
  • Industry
  • BULLZ Investment Bankers/Brokers/Service
  • ZVSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BULLZ Finance
  • ZVSA Health Care
  • Exchange
  • BULLZ Nasdaq
  • ZVSA Nasdaq
  • Market Cap
  • BULLZ N/A
  • ZVSA 2.5M
  • IPO Year
  • BULLZ N/A
  • ZVSA N/A
  • Fundamental
  • Price
  • BULLZ $1.73
  • ZVSA $0.63
  • Analyst Decision
  • BULLZ
  • ZVSA
  • Analyst Count
  • BULLZ 0
  • ZVSA 0
  • Target Price
  • BULLZ N/A
  • ZVSA N/A
  • AVG Volume (30 Days)
  • BULLZ N/A
  • ZVSA 4.1M
  • Earning Date
  • BULLZ N/A
  • ZVSA 05-12-2025
  • Dividend Yield
  • BULLZ N/A
  • ZVSA N/A
  • EPS Growth
  • BULLZ N/A
  • ZVSA N/A
  • EPS
  • BULLZ N/A
  • ZVSA N/A
  • Revenue
  • BULLZ N/A
  • ZVSA N/A
  • Revenue This Year
  • BULLZ N/A
  • ZVSA N/A
  • Revenue Next Year
  • BULLZ N/A
  • ZVSA N/A
  • P/E Ratio
  • BULLZ N/A
  • ZVSA N/A
  • Revenue Growth
  • BULLZ N/A
  • ZVSA N/A
  • 52 Week Low
  • BULLZ N/A
  • ZVSA $0.47
  • 52 Week High
  • BULLZ N/A
  • ZVSA $6.30
  • Technical
  • Relative Strength Index (RSI)
  • BULLZ N/A
  • ZVSA 52.27
  • Support Level
  • BULLZ N/A
  • ZVSA $0.50
  • Resistance Level
  • BULLZ N/A
  • ZVSA $0.74
  • Average True Range (ATR)
  • BULLZ 0.00
  • ZVSA 0.06
  • MACD
  • BULLZ 0.00
  • ZVSA 0.02
  • Stochastic Oscillator
  • BULLZ 0.00
  • ZVSA 56.69

About ZVSA ZyVersa Therapeutics Inc.

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Share on Social Networks: